4
Changes in Ownership
SpyGlass Pharma, Inc. Filed Acc 0001231919-26-000135
Director bought 3,690,000 shares at $16.00 ($59,040,000)
- Director acquired 4,331,117 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
RA CAPITAL MANAGEMENT, L.P. · Director
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-02-09 | Conversion : show line 1 in the form | +2,524,473 | 2,524,473 | I | ||
| 2026-02-09 | Conversion : show line 2 in the form | +1,806,644 | 1,806,644 | I | ||
| 2026-02-09 | Purchase : show line 3 in the form | +3,441,966 | $16.00 | $55,071,456 | 5,966,439 | I |
| 2026-02-09 | Purchase : show line 4 in the form | +248,034 | $16.00 | $3,968,544 | 2,054,678 | I |
| Open-market purchases · 3,690,000 sh · avg $16.00 · $59,040,000 | ||||||
Table II: Derivative
6 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-02-09 | Conversion : show line 5 in the form Series C-1 Preferred Stock | −1,150,941 | 0 | I |
| 2026-02-09 | Conversion : show line 6 in the form Series C-1 Preferred Stock | −767,294 | 0 | I |
| 2026-02-09 | Conversion : show line 7 in the form Series C-2 Preferred Stock | −1,150,941 | 0 | I |
| 2026-02-09 | Conversion : show line 8 in the form Series C-2 Preferred Stock | −767,294 | 0 | I |
| 2026-02-09 | Conversion : show line 9 in the form Series D Preferred Stock | −222,591 | 0 | I |
| 2026-02-09 | Conversion : show line 10 in the form Series D Preferred Stock | −272,056 | 0 | I |
Loading xslF345X05/form4-02112026_100217.xml…